Chapter title |
Clinical Development of Anti-mitotic Drugs in Cancer
|
---|---|
Chapter number | 6 |
Book title |
Cell Division Machinery and Disease
|
Published in |
Advances in experimental medicine and biology, June 2017
|
DOI | 10.1007/978-3-319-57127-0_6 |
Pubmed ID | |
Book ISBNs |
978-3-31-957125-6, 978-3-31-957127-0
|
Authors |
Olziersky, Anna-Maria, Labidi-Galy, S. Intidhar, Anna-Maria Olziersky, S. Intidhar Labidi-Galy |
Editors |
Monica Gotta, Patrick Meraldi |
Abstract |
Mitosis is one of the most fundamental processes of life by which a mammalian cell divides into two daughter cells. Mitosis has been an attractive target for anticancer therapies since fast proliferation was identified as one of the hallmarks of cancer cells. Despite efforts into developing specific inhibitors for mitotic kinases and kinesins, very few drugs have shown the efficiency of microtubule targeting-agents in cancer cells with paclitaxel being the most successful. A deeper translational research accompanying clinical trials of anti-mitotic drugs will help in identifying potent biomarkers predictive for response. Here, we review the current knowledge of mitosis targeting agents that have been tested so far in the clinics. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 30 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 23% |
Student > Master | 6 | 20% |
Researcher | 3 | 10% |
Student > Bachelor | 1 | 3% |
Student > Doctoral Student | 1 | 3% |
Other | 3 | 10% |
Unknown | 9 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 7 | 23% |
Agricultural and Biological Sciences | 5 | 17% |
Medicine and Dentistry | 4 | 13% |
Chemistry | 2 | 7% |
Economics, Econometrics and Finance | 1 | 3% |
Other | 3 | 10% |
Unknown | 8 | 27% |